Toutes les études
RecrutementPHASE3INTERVENTIONNEL

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

This study is looking for adults with a specific type of cancer called gastroenteropancreatic neuroendocrine tumours (GEP-NETs). This is for people whose cancer has spread and can't be removed by surgery, and where their previous treatment with Lutetium-177 has stopped working. The study is comparing a new medication called RYZ101 with existing standard treatments like Everolimus, Sunitinib, Octreotide, or Lanreotide. We want to find out if RYZ101 is safe, how it works in the body, and how effective it is at controlling the cancer compared to the standard options. The study aims to improve treatments for this type of cancer.

En un coup d'œil

Statut
Recrutement
Phase
PHASE3
Sponsor
RayzeBio, Inc.
Objectif d'inscription
338
Démarrer
24 mars 2022
Achèvement estimé
01 Dec 2030

De quoi parle cette étude ?

This research study is about a type of cancer called gastroenteropancreatic neuroendocrine tumours, often shortened to GEP-NETs. These cancers start in special cells found in your gut or pancreas. For some people, these cancers can grow or spread and can't be removed by surgery. When this happens, doctors use treatments that help control the cancer, but these treatments don't always stop the cancer from growing for good.

This study is looking for people whose GEP-NETs have continued to grow even after they've had a specific type of treatment called Lutetium-177. We are testing a new medicine called RYZ101. The main goal is to see if RYZ101 can be a safe and effective new option for these patients. We will compare it to common treatments that doctors already use, such as Everolimus, Sunitinib, Octreotide, or Lanreotide, to see if RYZ101 works better at controlling the cancer's growth and spread.

The study has two parts. The first part helps us understand the best dose of RYZ101 and how it moves through the body. The second and main part of the study will seriously compare this new medicine with standard treatments to understand its safety and how well it works. This research is important because it could lead to new and better ways to treat GEP-NETs for people who have limited options.

Points clés

  • This study is for adults with a specific type of GEP-NET cancer.
  • Your cancer must have progressed after previous Lutetium-177 treatment.
  • The study compares a new medicine (RYZ101) with standard treatments.
  • It aims to find out if RYZ101 is safe and more effective.
  • Participation involves regular hospital visits, tests, and medical monitoring.

Qui peut être éligible ?

To be considered for this study, you would need to have specific type of GEP-NET cancer that has been confirmed by a doctor. Your cancer must be well-differentiated (meaning the cells still look a bit like normal cells) and growing, and can't be removed by surgery. Importantly, your cancer must have grown even after you've already had Lutetium-177 treatment, and it should show up on a special type of scan called an SSTR-PET scan.

You also need to be generally well enough to take part, meaning you can mostly look after yourself. Your kidneys, blood, and liver need to be working properly, which will be checked with blood tests. There are some conditions that would mean you couldn't join. For example, if you've already had certain types of radiation treatment called radioembolisation or if you have serious heart problems like severe heart failure or very high blood pressure that can't be controlled with medicines. Also, if your diabetes is not well managed, you might not be able to participate.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Have you been diagnosed with an inoperable GEP-NET cancer?
  2. Has your GEP-NET cancer grown after Lutetium-177 (Lu-177) treatment?
  3. Do you feel generally well enough for a study, with good organ function?
  4. Do you have any serious heart conditions or very high blood pressure?
  5. Is your diabetes well controlled (if you have diabetes)?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, it will involve regular hospital visits, where you'll have check-ups, blood tests, and scans (like SSTR-PET scans) to monitor your health and how your cancer is responding. Some visits might be more frequent at the beginning. You will receive either the new medicine RYZ101 or one of the standard treatments (Everolimus, Sunitinib, Octreotide, or Lanreotide). You won't get to choose which treatment you receive; this is decided randomly, like flipping a coin. You will continue treatment for as long as it is benefiting you and you are tolerating it well. After your treatment ends, there will be follow-up calls or visits to see how you are doing. The total time you're involved in the study can vary, depending on how you respond to the treatment, but it will involve ongoing monitoring.

Risques et avantages potentiels

Taking part in any clinical study has potential benefits and risks. You might benefit from the new treatment RYZ101, which could potentially work better or have different side effects than existing options. However, there's no guarantee the treatment will work for you, and it's also possible you could receive a standard treatment. Like all medications, both RYZ101 and the standard treatments can cause side effects. The study team will carefully monitor you for these. You are always free to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (54)

  • Research Facility
    Code postal vérifié
    Phoenix, États-Unis· Actif, mais pas en recrutement
  • Research Facility
    Code postal vérifié
    Duarte, États-Unis· Terminé
  • Research Facility
    Code postal vérifié
    Irvine, United States· Recrutement
  • Research Facility
    Code postal vérifié
    Los Angeles, États-Unis· Actif, mais pas en recrutement
  • Research Facility
    Code postal vérifié
    Palo Alto, United States· Actif, mais pas en recrutement
  • Research Facility
    Code postal vérifié
    San Francisco, États-Unis· Actif, mais pas en recrutement
  • Research Facility
    Code postal vérifié
    New Haven, États-Unis· Actif, mais pas en recrutement
  • Research Facility
    Code postal vérifié
    Washington D.C., États-Unis· Actif, mais pas en recrutement
  • Research Facility
    Code postal vérifié
    Jacksonville, États-Unis· Actif, mais pas en recrutement
  • Research Facility
    Code postal vérifié
    Miami, États-Unis· Recrutement
  • Research Facility
    Code postal vérifié
    Tampa, États-Unis· Recrutement
  • Research Facility
    Code postal vérifié
    Atlanta, États-Unis· Actif, mais pas en recrutement

Questions fréquentes

What are GEP-NETs?

GEP-NETs are a type of cancer that starts in certain hormone-producing cells found in your gut (gastrointestinal tract) or pancreas.

What does 'inoperable' mean?

It means the cancer cannot be completely removed by surgery, often because it has spread or is in a difficult location.

What is Lutetium-177 treatment?

This is a type of radiation treatment where a radioactive substance is targeted directly to your cancer cells to help stop their growth.

Will I definitely get the new drug RYZ101?

No, you will be randomly assigned to receive either RYZ101 or one of the standard treatments that are already used for this type of cancer.

What is the aim of this study?

The study aims to see if the new medicine RYZ101 is safe and works better than current treatments for people with GEP-NETs whose cancer has progressed after Lutetium-177 treatment.

Comment en savoir plus

RayzeBio Clinical Trials

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ … vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.